全球開放式、一體化生物制藥能力和技術賦能平臺,專注于為全球生物制藥公司提供端到端研發服務的上市公司
藥明(ming)生(sheng)(sheng)(sheng)物(wu)(wu)(wu)(wu)(股票代碼:2269.HK)作為(wei)一家香港(gang)上(shang)市公(gong)司(si),是(shi)全球(qiu)(qiu)開放式、一體化生(sheng)(sheng)(sheng)物(wu)(wu)(wu)(wu)制藥能力(li)和技術賦能平臺。公(gong)司(si)為(wei)全球(qiu)(qiu)生(sheng)(sheng)(sheng)物(wu)(wu)(wu)(wu)制藥公(gong)司(si)和生(sheng)(sheng)(sheng)物(wu)(wu)(wu)(wu)技術公(gong)司(si)提供端到(dao)端研(yan)發服務,幫助任何人、任何公(gong)司(si)發現、開發及生(sheng)(sheng)(sheng)產生(sheng)(sheng)(sheng)物(wu)(wu)(wu)(wu)藥,實現從概念到(dao)商業(ye)(ye)化生(sheng)(sheng)(sheng)產的(de)全過程,加速全球(qiu)(qiu)生(sheng)(sheng)(sheng)物(wu)(wu)(wu)(wu)藥研(yan)發進程,降低研(yan)發成本,造福病患。截至2018年12月31日,在(zai)(zai)(zai)藥明(ming)生(sheng)(sheng)(sheng)物(wu)(wu)(wu)(wu)平臺上(shang)研(yan)發的(de)綜合(he)項(xiang)目達205個(ge),包括(kuo)97個(ge)處(chu)于(yu)臨床前研(yan)究階(jie)段(duan),94個(ge)在(zai)(zai)(zai)臨床早(zao)期(qi)(qi)(I期(qi)(qi),II期(qi)(qi))階(jie)段(duan),13個(ge)在(zai)(zai)(zai)后期(qi)(qi)臨床(III期(qi)(qi))以及1個(ge)在(zai)(zai)(zai)商業(ye)(ye)化生(sheng)(sheng)(sheng)產階(jie)段(duan)。預計到(dao)2022年,公(gong)司(si)在(zai)(zai)(zai)中國、愛爾蘭、新加坡、美國規(gui)劃的(de)生(sheng)(sheng)(sheng)物(wu)(wu)(wu)(wu)制藥生(sheng)(sheng)(sheng)產基地合(he)計產能約(yue)22萬(wan)升,這將有力(li)促使公(gong)司(si)通過健全強大的(de)全球(qiu)(qiu)供應鏈網(wang)絡為(wei)客(ke)戶提供符合(he)全球(qiu)(qiu)質量(liang)標準的(de)生(sheng)(sheng)(sheng)物(wu)(wu)(wu)(wu)藥。
藥明生(sheng)物是全球開(kai)放式、一體化生(sheng)物制(zhi)藥能力和技術賦(fu)能平(ping)臺。公(gong)(gong)司(si)為(wei)全球生(sheng)物制(zhi)藥公(gong)(gong)司(si)和生(sheng)物技術公(gong)(gong)司(si)提供端到端研(yan)發(fa)(fa)服(fu)務,幫助任何(he)人、任何(he)公(gong)(gong)司(si)發(fa)(fa)現、開(kai)發(fa)(fa)及(ji)生(sheng)產(chan)生(sheng)物藥,實現從概念(nian)到商業化生(sheng)產(chan)的全過(guo)程(cheng)。公(gong)(gong)司(si)通(tong)過(guo)高(gao)質量、一體化服(fu)務賦(fu)能全球客戶,提高(gao)研(yan)發(fa)(fa)效率,降低研(yan)發(fa)(fa)成本,進(jin)一步加速(su)生(sheng)物藥研(yan)發(fa)(fa)進(jin)程(cheng)。